Multiplexed Biomarkers for staging Alzheimer???s Disease

描述(申请人提供)：随着AD的日益流行，在AD的早期阶段准确和可靠地诊断AD的能力已成为公共卫生的优先事项。临床病理研究表明，AD的病理在引起的认知损害引起医学关注之前10-15年就开始了。因此，能够在AD早期阶段发现AD病理并预测痴呆发病的生物标志物对于患者护理和有效的临床试验设计将是非常宝贵的。多重免疫分析平台，如我们建议开发的平台，允许同时定量许多分析物，并通过遵守临床实验室改进修正案(CLIA)标准，可以进行临床试验工作。我们的多重、低样本量、超灵敏分析为研究脑脊液中一系列潜在的致病标志物提供了机会，这可能导致非常有用的疾病诊断工具。 公共卫生相关性：拟议合作研究的总体目标(第一阶段和第二阶段)是开发一个具有成本效益、易于使用、基于荧光光学的高灵敏度分析平台，用于测量与阿尔茨海默病(AD)相关的新型脑脊液(CSF)生物标记物。

DESCRIPTION (provided by applicant): With the growing prevalence of AD, the ability to accurately and reliably diagnose AD in its earliest stages has become a public health priority. Clinicopathological studies suggest that AD pathology begins 10-15 years before the resulting cognitive impairment draws medical attention. Biomarkers that can detect AD pathology in its early stages and predict dementia onset would, therefore, be invaluable for patient care and efficient clinical trial design. Multiplex immunoassay platforms such as the one we are proposing to develop, allow for the simultaneous quantitation of many analytes, and by adhering to clinical laboratory improvement amendments (CLIA) standards, are amenable for clinical trial work. Our multiplexed, low sample volume, ultra-sensitive assay open up the opportunity to study a wide range of potential pathogenic markers in CSF, which could lead to very informative diagnostic tools for the disease. PUBLIC HEALTH RELEVANCE: The overall goal (PHASE I and II) of the proposed collaborative research is to develop a cost effective, easy-to-use, fluorescence optics based high sensitive assay platform for measuring novel cerebrospinal fluid (CSF) biomarkers associated with Alzheimer's Disease (AD).